ReviewRheumatology (Oxford, England)2019
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Review in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Optimizing management of immune checkpoint inhibitor-induced inflammatory arthritis: A case series and literature review.Experimental and therapeutic medicine · 2026Article
- Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study.Scientific reports · 2026Observational
- Clinical Value ofDiagnostics (Basel, Switzerland) · 2026Article
- An atypical presentation of immune checkpoint inhibitor associated myositis with normal creatine kinase: a case report.Frontiers in immunology · 2025Article
- An underrecognized association: immune checkpoint inhibitor-related aortitis, a case report with the review of the literature.International cancer conference journal · 2024Article
- Case report: Inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab.Frontiers in immunology · 2024Article
- Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.The oncologist · 2023Article
- [Rheumatological side effects of checkpoint inhibitors and their treatment].Zeitschrift fur Rheumatologie · 2023Review
- Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma.IJU case reports · 2023Article
- Atezolizumab-induced scleroderma: a rare complication.BMJ case reports · 2021Article
- Diagnostic Dilemma of Paraneoplastic Rheumatic Disorders: Case Series and Narrative Review.Cureus · 2021Article
- Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.Cancer metastasis reviews · 2021Review
- Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy.Biology · 2021Review
- Spectrum and impact of checkpoint inhibitor-induced irAEs.Nature reviews. Rheumatology · 2021Article
- Immune checkpoint inhibitor-induced musculoskeletal manifestations.Rheumatology international · 2021Review
- Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
- Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compared with conventional cancer therapies, the spectrum of toxicities observed with checkpoint inhibitors is unique and can affect any organ system. Arthralgia and myalgia were by far the most commonly reported rheumatic immune-related adverse events in clinical trials, and there is now a growing number of case series and reports describing clinical features of de novo rheumatic immune-related adverse events, which will be the focus of this review. Some patients develop genuine classic rheumatic and musculoskeletal diseases, but a number of rheumatic immune-related adverse events mimic rheumatic and musculoskeletal diseases with atypical features, mainly polymyalgia rheumatica, rheumatoid arthritis and myositis, as well as several systemic conditions, including sicca syndrome, vasculitis, sarcoidosis, systemic sclerosis and lupus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.